Gyre Therapeutics, Inc. GYRE Accrued expenses and other liabilities
Accrued expenses and other liabilities at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesAndOtherLiabilities.
The official record: Gyre Therapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Gyre Therapeutics, Inc.'s accrued expenses and other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Gyre Therapeutics, Inc.'s accrued expenses and other liabilities?
- Gyre Therapeutics, Inc. (GYRE) reported accrued expenses and other liabilities of $15.42M in Q1 2026.
- How has Gyre Therapeutics, Inc.'s accrued expenses and other liabilities changed year-over-year?
- Gyre Therapeutics, Inc.'s accrued expenses and other liabilities decreased by 10.6% year-over-year, from $17.24M to $15.42M.
- What is the long-term trend for Gyre Therapeutics, Inc.'s accrued expenses and other liabilities?
- Over 3 years (2022 to 2025), Gyre Therapeutics, Inc.'s accrued expenses and other liabilities has grown at a 15.7% compound annual growth rate (CAGR), from $9.26M to $14.36M.